| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Kezar Life Sciences, Inc.
13D/A
KZR · 49372L100
|
8.5% |
1/16/2025
Event 12/3/2024
|
||||
| Morningside Venture Investments Limited | 0% | |||||
| Frances Anne Elizabeth Richard | 0% | |||||
| Jill Marie Franklin | 0% | |||||
| Peter Stuart Allenby Edwards | 0% | |||||
| Cheung Ka Ho | 0% | |||||
| Equal Talent Investments Limited | 8.5% | |||||
| Suk Ying Pauli Ng | 8.5% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.